**This article was originally published for ROTY subscribers on June 3, but has been updated where necessary. Despite recent share price appreciation, the story remains in early innings with substantial upside potential ahead as we await efficacy data for the AFM24 program.
Shares of German biotech firm Affimed (NASDAQ:AFMD) have risen by 145% since my initial recommendation and by 65% since my October update. At the time, promising science and lofty goals ("giving back to patients the innate ability to combat cancer") were trumped by seemingly slow progress in the clinic, prompting